Publications in collaboration with researchers from University of Paris-Sorbonne (19)

2024

  1. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

    The Lancet Rheumatology, Vol. 6, Núm. 6, pp. e374-e383

2022

  1. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

    Annals of the rheumatic diseases, Vol. 81, Núm. 7, pp. 970-978

  2. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

    Annals of the rheumatic diseases, Vol. 81, Núm. 5, pp. 695-709

2021

  1. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 9, pp. 1137-1146

  2. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

    European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539

2017

  1. 2016 update of the EULAR recommendations for the management of early arthritis

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 6, pp. 948-959

  2. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

  3. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: An analysis of 1588 patients

    Rheumatology (United Kingdom), Vol. 56, Núm. 9, pp. 1573-1578

2016

  1. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: A multicentre, randomised, double-blind, non-inferiority trial versus celecoxib

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 37-44

  2. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 6, pp. 965-973

2015

  1. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 1, pp. 8-13

  2. Development of patient-centred standards of care for osteoarthritis in Europe: The eumusc.net-project

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 6, pp. 1145-1149

2014

  1. Facilitators to implement standards of care for rheumatoid arthritis and osteoarthritis: The EUMUSC.NET project

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 8, pp. 1545-1548

2012

  1. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Revmatologiia (Bulgaria), Vol. 20, Núm. 2, pp. 5-16

2011

  1. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: A EULAR initiative

    Annals of the Rheumatic Diseases, Vol. 70, Núm. 6, pp. 935-942

2010

  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 6, pp. 964-975

  2. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 4, pp. 631-637

2009

  1. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: A EULAR initiative

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 11, pp. 1680-1685

  2. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 7, pp. 1086-1093